Fetal bovine serum (FBS) is an essential growth supplement used in eukaryotic cell culture media formulated from blood taken from fetal calves during slaughter for veal meat production. It provides attachment factors, growth factors, proteins, and other components that support cell growth. However, obtaining FBS is expensive, involves ethical concerns, and quality can vary between batches. As a result, many researchers are seeking out more affordable and consistent substitutes.
The fetal bovine serum market is estimated to be valued at USD 1.86 Bn in 2024 and is expected to reach USD 4.54 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 13.6% from 2024 to 2031.
Key applications of FBS include biopharmaceutical production, cancer research, drug discovery, regenerative medicine and therapy, stem cell research, and vaccine production. Its critical role in basic cell culture has led to increased demand, outpacing supply at times. However, concerns over cost, inconsistent quality, and ethical sourcing have driven innovation towards animal product-free and serum-free solutions.
Key Takeaways
Key Players: Key players in the fetal bovine serum market Merck KGaA, Thermo Fisher Scientific Inc., HiMedia Laboratories, Bio-Techne, PAN-Biotech, Atlas Biologicals, Inc., Rocky Mountain Biologicals, Cytiva, Sartorius AG, and SeraCare Life Sciences.
Growing Demand: Advancements in cell culture and biopharmaceutical manufacturing have increased the need for a reliable and plentiful source of growth supplements like FBS. Researchers across industries require large volumes, driving up worldwide Fetal Bovine Serum Market Demand.
Global Expansion: Leading producers are expanding operations through acquisitions, new facilities, and regional distribution centers. For example, Thermo Fisher opened new FBS production plants in India and China in 2022 to better serve the Asia Pacific market.
Market Key Trends
One of the major trends in the fetal bovine serum market is a shift towards serum-free and animal product-free cell culture media. Increased awareness of ethical concerns and highly variable quality of FBS have accelerated research into chemically-defined formulations that eliminate the need for animal-derived components. Some key players have had success commercializing proprietary serum- and xenoprotein-free media optimized for high-yielding cell lines. If these substitutes can meet performance and economic requirements, they may gradually replace FBS, altering the long-term outlook of this market.
Porter's Analysis
Threat of new entrants: Serum production requires significant capital investment and regulatory approvals.
Bargaining power of buyers: Large biotech companies can negotiate lower prices due to bulk purchases.
Bargaining power of suppliers: Few suppliers dominate the market and control the global supply of FBS.
Threat of new substitutes: Researchers are developing synthetic alternatives but none have gained widespread acceptance yet.
Competitive rivalry: Major players compete on differentiation, customer service and intellectual property.
North America accounts for over 45% of the global market value due to presence of top pharmaceutical companies and research organizations in the US and Canada. Extensive R&D activities in biotechnology and pharmaceutical sectors drive the high demand.
The Asia Pacific region is expected to grow at the fastest pace during the forecast period. This is attributed to increasing pharmaceutical production and rising investment in bioscience research in China, India, and other Asia Pacific countries. Growing biotech and pharmaceutical industries are expanding the application base of fetal bovine serum in the region.
Get This Report in Japanese Language
Get This Report in Korean Language
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
